

## 🔅 health net.

HEDIS<sup>®</sup> Tip Sheet | Effectiveness of Care Measure International Normalizing Ratio (INR) Monitoring for Individuals on Warfarin

. . . . . . . . . . . . .

## Learn how to improve INR monitoring for individuals on Warfarin by using this tip sheet for key details about the measure, codes and best practices.

Measure

Eligi pop The percentage of patients ages 18 years and older who had at least one 56-day interval of Warfarin therapy and who received at least one international normalized ratio (INR) monitoring test during each 56-day interval with active Warfarin therapy.

A higher rate indicates better performance.

	Age	18 years and older as of the first day of the measurement year (MY).
	Continuous enrollment	The treatment period
ible	Allowable gap	None
oulation	Required exclusions	<ul> <li>Exclude patients with a laboratory or medical claim for INR home monitoring during the measurement year.</li> <li>Exclude patients who died during the MY.</li> </ul>
	Event/diagnosis	Patients who have been dispensed Warfarin during the MY. Note: Pharmacy claims determine eligibility.

	Denominator	The eligible population.
Administrative specification	Numerator	Patients who received at least one INR monitoring test during, or were hospitalized during, each 56-day interval during the treatment period. Note: Lab or hospitalization claims determine compliance

<sup>\*</sup>Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

## INR Monitoring for Individuals on Warfarin (cont.)

Coding	Measure	СРТ	CPT II
guidance	INR Test – prothrombin time	85610	N/A
	INR measurement performed	N/A	3555F
• • • • • • • • • • • •		•••••	• • • • • • • • • • • • • • • • • • • •
Exclusion	Measure	СРТ	HCPCS
coding guidance	INR Home Monitoring Exclusion	93792-93793	G0248-G0250
-	month, but some patients ma	y require testing as o	
Best	<ul> <li>month, but some patients ma</li> <li>Discuss the common signs an patient<sup>2</sup>.</li> </ul>	y require testing as o d symptoms of bleed	
-	<ul> <li>month, but some patients ma</li> <li>Discuss the common signs an patient<sup>2</sup>.</li> <li>Advise patients to take their V that the INR test result will be</li> </ul>	y require testing as o d symptoms of bleed Varfarin in the evenin back in time to chan	ften as twice a week <sup>1</sup> . ing, blood clots, and a thrombotic event with g and schedule their INR test in the morning, ge that day's Warfarin dose if needed.
Best	<ul> <li>month, but some patients ma</li> <li>Discuss the common signs an patient<sup>2</sup>.</li> <li>Advise patients to take their W that the INR test result will be</li> <li>Educate patients on staying a</li> </ul>	y require testing as o d symptoms of bleed Varfarin in the evenin back in time to chan way from foods high i	ften as twice a week <sup>1</sup> . ing, blood clots, and a thrombotic event with g and schedule their INR test in the morning, ge that day's Warfarin dose if needed. n vitamin K, which will lower the INR test resu
Best	<ul> <li>month, but some patients ma</li> <li>Discuss the common signs an patient<sup>2</sup>.</li> <li>Advise patients to take their V that the INR test result will be</li> </ul>	y require testing as o d symptoms of bleed Varfarin in the evenin back in time to chan way from foods high i or the patient to deve	ften as twice a week <sup>1</sup> . ing, blood clots, and a thrombotic event with g and schedule their INR test in the morning, ge that day's Warfarin dose if needed. n vitamin K, which will lower the INR test resu lop a blood clot.
Best	<ul> <li>month, but some patients ma</li> <li>Discuss the common signs an patient<sup>2</sup>.</li> <li>Advise patients to take their V that the INR test result will be</li> <li>Educate patients on staying a and cause an increased risk for</li> <li>Schedule follow-up appointm</li> <li>Use Table 4, <u>Provider Checkling</u></li> </ul>	y require testing as o d symptoms of bleed Varfarin in the evening back in time to chan way from foods high i or the patient to deve ents prior to patient l st for Evaluation of An	ften as twice a week <sup>1</sup> . ing, blood clots, and a thrombotic event with g and schedule their INR test in the morning, ge that day's Warfarin dose if needed. n vitamin K, which will lower the INR test resu lop a blood clot.
Best	<ul> <li>month, but some patients ma</li> <li>Discuss the common signs an patient<sup>2</sup>.</li> <li>Advise patients to take their W that the INR test result will be</li> <li>Educate patients on staying a and cause an increased risk for</li> <li>Schedule follow-up appointmediate</li> </ul>	y require testing as o d symptoms of bleed Varfarin in the evenin back in time to chan way from foods high i or the patient to deve ents prior to patient l st for Evaluation of An <u>herapy Toolkit</u> .	ften as twice a week <sup>1</sup> . ing, blood clots, and a thrombotic event with g and schedule their INR test in the morning, s ge that day's Warfarin dose if needed. n vitamin K, which will lower the INR test resu lop a blood clot. eaving the office. <u>ticoagulation-Associated Bleeding<sup>3</sup></u> .

## References

<sup>1</sup>North American Thrombosis Forum. (2023). A Guide to INR levels.

<sup>2</sup> Jaffer, Bragg. (2003). Practical Tips for Warfarin Dosing and Monitoring.

 $^{3}\,\mbox{Anticoagulation}$  Clinic of the Cleveland Clinic PDF page 9

 $^{\rm 4}\,{\rm Anticoagulation}$  Clinic of the Cleveland Clinic PDF page 6